Literature DB >> 16371869

Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Côte d'Ivoire: ANRS 1278 study.

Narcisse Elenga1, Kouakou Alain Kouakoussui, Dominique Bonard, Patricia Fassinou, Marie-France Anaky, Marie-Louise Wemin, Flore Dick-Amon-Tanoh, François Rouet, Véronique Vincent, Philippe Msellati.   

Abstract

INTRODUCTION: Most data on tuberculosis in human immunodeficiency virus (HIV)-infected children in Africa come from hospital-based and cross-sectional studies.
OBJECTIVES: To estimate the incidence of tuberculosis in HIV-infected children participating in an observational cohort.
METHODS: HIV-infected children in Abidjan, Côte d'Ivoire, are followed in a prospective cohort. At enrollment, all children had a physical examination, CD4 lymphocyte counts, chest radiograph and a tuberculin test. Quarterly follow-up visits are organized. All patients with suspected tuberculosis undergo specific investigations including gastric aspiration and culture. All isolates are tested for susceptibility.
RESULTS: From October 2000 to December 2003, 129 girls and 153 boys were recruited. Of children without a current or previous diagnosis of tuberculosis, 6.5% (13 of 199) had a tuberculin test result of >5 mm, compared with 17.5% of children (10 of 57) with current or previous tuberculosis (P < 0.02). Forty-eight children (17%) had a history of treated tuberculosis, and 27 children were being treated for tuberculosis at enrollment or during the first month of follow-up. Eleven children were diagnosed with tuberculosis after the first month of follow-up, and the diagnosis of mycobacterial infection was confirmed in 7 cases. Of 5 tested isolates of Mycobacterium tuberculosis, 3 were resistant to at least 1 antitubercular drug. Cumulative incidence of tuberculosis was 2060/100,000 at 12 months, 3390/100,000 at 2 years and 5930/100,000 at 3 years. The 3-year risk was 12,400/100,000 in immunocompromised children (CD4 <15%) and 3300/100,000 in other children (P < 0.0001).
CONCLUSION: The risk of tuberculosis among HIV-infected children in Côte d'Ivoire is strongly associated with the degree of immunodeficiency in HIV infection.

Entities:  

Mesh:

Year:  2005        PMID: 16371869     DOI: 10.1097/01.inf.0000190008.91534.b7

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  22 in total

1.  Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya.

Authors:  L L Abuogi; C Mwachari; H H Leslie; S B Shade; J Otieno; N Yienya; L Sanguli; E Amukoye; C R Cohen
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

2.  The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Olatunji O Adetokunboh; Ajibola Awotiwon; Duduzile Ndwandwe; Olalekan A Uthman; Charles S Wiysonge
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

3.  Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.

Authors:  Sampson Antwi; Hongmei Yang; Anthony Enimil; Anima M Sarfo; Fizza S Gillani; Daniel Ansong; Albert Dompreh; Antoinette Orstin; Theresa Opoku; Dennis Bosomtwe; Lubbe Wiesner; Jennifer Norman; Charles A Peloquin; Awewura Kwara
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 4.  Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.

Authors:  Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen
Journal:  Lancet       Date:  2014-03-24       Impact factor: 79.321

5.  Tuberculosis in human immunodeficiency virus-infected children starting antiretroviral therapy in Côte d'Ivoire.

Authors:  A F Auld; M Z Tuho; K A Ekra; J Kouakou; R W Shiraishi; G Adjorlolo-Johnson; R Marlink; T V Ellerbrock
Journal:  Int J Tuberc Lung Dis       Date:  2014-04       Impact factor: 2.373

6.  Morbidity and health care resource utilization in HIV-infected children after antiretroviral therapy initiation in Côte d'Ivoire, 2004-2009.

Authors:  Sophie Desmonde; Jean-Bosco Essanin; Addi E Aka; Eugène Messou; Madeleine Amorissani-Folquet; Virginie Rondeau; Andrea Ciaranello; Valériane Leroy
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

7.  Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.

Authors:  Andrew Edmonds; Jean Lusiama; Sonia Napravnik; Faustin Kitetele; Annelies Van Rie; Frieda Behets
Journal:  Int J Epidemiol       Date:  2009-05-15       Impact factor: 7.196

Review 8.  Isoniazid-resistant tuberculosis in children: a systematic review.

Authors:  Courtney M Yuen; Arielle W Tolman; Ted Cohen; Jonathan B Parr; Salmaan Keshavjee; Mercedes C Becerra
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

9.  Challenges of Childhood TB/HIV Management in Malawi.

Authors:  G Poerksen; Pn Kazembe; Sm Graham
Journal:  Malawi Med J       Date:  2007-12       Impact factor: 0.875

10.  Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices.

Authors:  Marie Ballif; Lorna Renner; Jean Claude Dusingize; Valeriane Leroy; Samuel Ayaya; Kara Wools-Kaloustian; Claudia P Cortes; Catherine C McGowan; Claire Graber; Anna M Mandalakas; Lynne M Mofenson; Matthias Egger; Ketut Dewi Kumara Wati; Revathy Nallusamy; Gary Reubenson; Mary-Ann Davies; Lukas Fenner
Journal:  J Pediatric Infect Dis Soc       Date:  2014-03-28       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.